When: $352 daily close (200 SMA intraday break on volume >10M)

Then: Exit residual position

When: $355-390

Then: Hold with put protection; do not trade

HOLD core position; measured trim to benchmark weight defensible for overweight holders, but SELL removes optionality and locks in a decision one week before the Q3 catalyst

• Entry at 385 and stop at 400 is a procedural error—stop above entry for a sell recommendation doesn't make sense unless 400 is a re-entry trigger, but the proposal doesn't state this clearly
• Technical setup: 365-388 box, 200 SMA at 353 holding, 10 EMA curling up, MACD histogram first positive bar since August 2, RSI at 46 recovering from low 30s without capitulation print
• Q1 EPS 6.90, Q2 EPS 6.04 totaling 12.94—three consecutive quarters of margin recovery; forward EPS estimate is a trajectory, not a hope
• 86% beat probability vs 14% miss tail on 10/13 print; aggressive analyst overweights downside tail underweighting asymmetric positioning
• Forward PE of 16.6x: aggressive analyst applies wrong base rate—2024/2025 collapses were medical cost cycle events, not transition-year events
• H1 2026 FCF of 18.4 billion exceeds all of 2025; net debt down 9.3 billion in two quarters; deleveraging is real
• UNH characteristics: 0.62 beta (low-beta defensive), 2.45% dividend yield, 59% payout ratio, 24 billion TTM FCF, income buyers accumulate on compression
• Risk-reward from 376: ~5% down on tail event versus 15-20% upside on clean recovery print; asymmetric trade is not SELL
• Most major bottoms in mega-cap defensive names don't have capitulation prints—absence of capitulation is evidence sellers absorbed quietly, not bearish
• SELL crystallizes losses, removes dividend income stream, pays tax friction, and forces redeployment at exactly the wrong moment with no clear alternative at 2002-high 10Y

→ vs aggressive: Stop logic is mechanically flawed: entry at 385, stop at 400 (above entry) for a sell treats 400 as a loss cut, creating a forced buy-high, sell-low sequence when stock tests 50 SMA at 390

→ vs aggressive: Coiled spring thesis assumes macro should win direction, but coiled ranges resolve in the direction the next catalyst takes them, not macro backdrop; technicals are not confirming the SELL thesis

→ vs aggressive: Applying small-cap momentum playbook to a 338B mega-cap defensive healthcare giant is the wrong tool for the job; institutional holders don't capitulate like small-cap momentum players

→ vs aggressive: Forward PE of 16.6x trap thesis anchors to historical pattern that no longer applies after margin cycle has visibly cleared; if consensus revision doesn't materialize, we sold at bottom of recovery cycle

→ vs aggressive: Defensive rotation argument is backwards—defensive rotation is exactly what you want in ripping rates environment; capital flees duration risk and seeks stable cash flows with pricing power

→ vs aggressive: FCF protection thesis breaks down: elite FCF plus deleveraging plus dividend growth plus sub-17 multiple plus defensive sector flows equals a setup where multiple has a floor

→ vs aggressive: Capitulation thesis misses that institutional/patient holder base absorbs sellers quietly; absence of capitulation print in mega-cap defensive is a bullish signal, not bearish

→ vs aggressive: SELL removes optionality and locks in decision one week before Q3 catalyst that will validate or invalidate recovery trajectory; patient holding is conservative version of aggression

REDUCE TO BENCHMARK WEIGHT (HOLD). Use 200 SMA weekly close at 353 as structural exit trigger. Use 50 SMA reclaim with MACD line crossing above zero as re-engagement trigger. Let 10/13 be the tactical decision point, not the strategic one.

• Trim to benchmark weight, not below; keep dividend income stream and exposure to the 86 percent beat probability into 10/13
• 200 SMA at 353 weekly close is the structural exit trigger; if broken, position comes out entirely
• 50 SMA reclaim with MACD line crossing above zero is the re-engagement trigger to add back to fuller weight
• A 400 stop above a 385 entry on a trim does not function as a stop loss; it functions as a re-engagement trigger
• Do not dismiss FCF entirely: $24 billion trailing FCF plus deleveraging plus dividend creates a multiple floor
• RSI holding 30s instead of breaking 30 in a mega-cap defensive (0.62 beta, $338 billion market cap) is evidence sellers have been absorbed
• Polymarket 86 percent beat probability is priced for headline beat but not for trajectory implication of three consecutive clean quarters
• Forward EPS range is $19.50 to $22.61; multiple compression risk adds 12 to 15 percent downside on top of business risk
• 10/13 is the tactical decision point; CMS Final Rate Notice for 2027 MA in Q4 is the larger catalyst for the multiple
• If 10/13 prints a clean beat with constructive guidance and stock rallies 5 to 7 percent, base exposure must be maintained to participate

→ vs aggressive: Macro is a continuous variable while the 365 to 388 range resolves on discrete catalyst at 10/13; betting on macro over catalyst is wrong framework

→ vs aggressive: Capitulation argument applies a small-cap momentum playbook incorrectly to a mega-cap defensive; RSI holding 30s is bullish signal that bid is real

→ vs aggressive: FCF dismissal is too clean; $24 billion trailing FCF, $9.3 billion deleveraging, 2.45 percent yield creates a multiple floor even if it does not expand

→ vs aggressive: SELL crystallizes losses seven trading days before the event that will actually move the stock; wrong timing

→ vs conservative: HOLD at full weight accepts continuous drawdown risk of 10 to 15 percent before 10/13 even arrives if macro or regulatory risks materialize

→ vs conservative: Consensus EPS is anchored to top of $19.50 to $22.61 range; 10 to 15 percent downward revision risk is real and not priced

→ vs conservative: Defensive rotation does not automatically mean rotation into UNH; 50 SMA rejection for three months shows defensive flows are not landing in this name

→ vs conservative: The yield floor is closer to 360 than 390, a meaningful difference from current 376 price